Monte Rosa Therapeutics (NASDAQ:GLUE) just reported results for the fourth quarter of 2023.
- Monte Rosa Therapeutics reported earnings per share of -58 cents. This was below the analyst estimate for EPS of -33 cents.
- The company did not report any revenue for the quarter.